Please login to the form below

Not currently logged in
Email:
Password:

Andrew Gengos joins ImmunoCellular as CEO

Will lead company as it initiates phase II trials investigating brain tumour vaccine

ImmunoCellular Andre GengosCancer specialist ImmunoCellular Therapeutics has appointed Andrew Gengos as president and CEO.

Gengos joins from Neuraltus Pharmaceuticals, where he also served as president and CEO, and becomes the permanent replacement for Dr Manish Singh who left the company in August 2012 to "pursue other opportunities".

Since August, ImmunoCellular's founder and chief scientific officer Dr John Yo has served as interim CEO.

Gengos joins at an important time for ImmunoCellular, with the company having recently commenced a phase II trial investigating its lead product candidate ICT-107, a potential cell-based vaccine for glioblastoma brain tumours.

ImmunoCellular will benefit from Gengos's experience in neuroscience during his time at Neuraltus, which specialises in therapies for neurodegenerative diseases, such as amyotrophic lateral sclerosis and Parkinson's disease.

“Joining ImmunoCellular is an extraordinary opportunity to help build a leading biopharmaceutical company with the potential to transform the treatment of cancer,” said Gengos. “I believe that the company's immunotherapy platform that targets both cancer cells and cancer stem cells represents a promising and innovative medical breakthrough.”

Prior to joining Neuraltus spent more than seven years at Amgen, holding such positions as VP, strategy and corporate development.

He has also spent time at Dynavax Technologies, Chiron Corporation and McKinsey & Company.

5th December 2012

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics